NCT00038675View on ClinicalTrials.gov

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

NACompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Chronic Myelomonocytic LeukemiaChronic Myeloid LeukemiaPolycythemia VeraHypereosinophilic SyndromeMastocytosis
Interventions
DRUG

Imatinib Mesylate (Gleevec)

Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER